iCAD, Inc.

NasdaqCM ICAD

iCAD, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2024: USD 18.94 M

iCAD, Inc. Revenue is USD 18.94 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -14.70% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • iCAD, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 22.20 M, a -24.12% change year over year.
  • iCAD, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 29.26 M, a -19.35% change year over year.
  • iCAD, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 36.28 M, a 26.74% change year over year.
  • iCAD, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 28.63 M.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
Loading...
SV Wall Street
NasdaqCM: ICAD

iCAD, Inc.

CEO Ms. Dana R. Brown
IPO Date Dec. 13, 1984
Location United States
Headquarters 98 Spit Brook Road
Employees 67
Sector Healthcare
Industries
Description

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

Similar companies

NVNO

enVVeno Medical Corporation

USD 3.27

-0.61%

MOVE

Movano Inc.

USD 5.01

-4.39%

FNA

Paragon 28, Inc.

USD 13.01

-0.08%

SSKN

STRATA Skin Sciences, Inc.

USD 2.83

4.04%

SGHT

Sight Sciences, Inc.

USD 2.73

-2.50%

AXGN

AxoGen, Inc.

USD 17.92

-1.59%

SRDX

Surmodics, Inc.

USD 34.07

0.09%

CVRX

CVRx, Inc.

USD 15.46

-3.25%

SIBN

SI-BONE, Inc.

USD 17.02

1.55%

NVRO

Nevro Corp.

USD 4.98

-1.77%

ESTA

Establishment Labs Holdings Inc.

USD 32.05

-5.07%

LNSR

LENSAR, Inc.

USD 10.65

-4.05%

StockViz Staff

February 4, 2025

Any question? Send us an email